Dana-Farber Cancer Institute is launching Solavia Decision Suite, a new oncology decision-support platform designed to bring evidence-based cancer treatment guidance directly into clinicians’ workflows.
Co-developed with NYU Langone Health, the platform aims to help oncologists navigate increasingly complex treatment decisions by providing context-specific guidance informed by Dana-Farber’s oncology expertise.
Solavia is embedded within the electronic health record and provides treatment guidance based on factors including a patient’s disease, stage, prior treatment, and other clinical considerations.
Supporting Complex Cancer Treatment Decisions
The rapid pace of cancer drug development, clinical trial results, and regulatory approvals has made it increasingly difficult for clinicians to stay current with the latest treatment options and evidence.
Solavia was developed to address this challenge by guiding clinicians through a structured decision-making process within their existing clinical workflow.
The platform also provides supporting evidence and literature citations to help physicians evaluate potential treatment options.
According to Dana-Farber, the goal is to extend specialized oncology expertise beyond the Institute itself and make evidence-based treatment pathways available at the point where treatment decisions are being made.
David Jackman, MD, Medical Director of Clinical Pathways and New Business Initiatives at Dana-Farber Cancer Institute, said:
“Cancer treatment is evolving at an extraordinary pace, and it is increasingly challenging for any individual clinician to keep up with every new development across every disease and treatment setting.”
He added:
“Solavia creates a new way to put Dana-Farber’s collective oncology expertise and evidence-based treatment guidance directly into the clinical workflow, helping physicians make informed treatment decisions at the point of care.”
Built on Dana-Farber’s Oncology Treatment Pathways
Solavia builds on more than a decade of work at Dana-Farber developing oncology treatment pathways.
These pathways translate the expertise of subspecialists and medical leadership into specific recommendations intended to support patient care.
They are continually reviewed and updated by expert Dana-Farber-led committees as new evidence emerges, including regulatory approvals, clinical research findings, and the collective clinical experience of Dana-Farber faculty.
The new platform provides a more integrated and scalable way to deliver this guidance within the clinical workflow while expanding its potential reach beyond Dana-Farber.
Clinical Judgment Remains Central
Dana-Farber emphasized that Solavia is intended to complement, rather than replace, clinical judgment.
Clinicians remain responsible for treatment decisions and can take into account the individual circumstances of each patient when determining the most appropriate course of care.
Jackman said:
“Ultimately, Solavia is about putting the right information in front of clinicians at the right time, while keeping the patient at the center of every decision.”
He continued:
“We want physicians to have confidence that the treatment recommendations they are considering reflect the latest evidence as well as the collective expertise of Dana-Farber’s oncology community.”
Co-Developed With NYU Langone Health
Solavia was co-developed by Dana-Farber Cancer Institute and NYU Langone Health.
The collaboration combines Dana-Farber’s experience in oncology treatment pathways with NYU Langone’s expertise in health information technology and in developing applications integrated within the Epic electronic health record.
NYU Langone launched Solavia internally in June and announced the platform’s commercial availability in July.
At Dana-Farber, the platform will be introduced in phases beginning in September 2026.
More broadly, Dana-Farber said Solavia represents a new model for extending specialized oncology expertise beyond academic cancer centers by bringing evidence-based treatment guidance directly into clinicians’ workflows and, ultimately, closer to the patients they serve.
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is a global cancer research and treatment center focused on scientific discovery, clinical care, education, community engagement, and advocacy.
The Institute conducts more than 1,200 clinical trials and works to translate scientific discoveries into new treatments for patients.
Dana-Farber is a federally designated Comprehensive Cancer Center and a principal teaching affiliate of Harvard Medical School.
Read further on OncoDaily: Dana-Farber Study Links CDK2 Activity With Response to Immune Checkpoint Blockade
